FILE - This April 20, 2010, file photo shows an exterior view of Amgen offices in Fremont, Calif. Amgen Inc. agreed on Tuesday, Dec. 18, 2012, to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. (AP Photo/Paul Sakuma, File)
News Summary: Amgen 4Q profit drops, costs rise
Published: 01:51:07 AM, Thu 24 January 2013 UTC
PROFIT SLUMP: Biotech giant Amgen Inc.'s fourth-quarter net income dropped 16 percent to $788 million, or $1.01 per share, due to higher spending on production, marketing, research and other items.
SALES SURGE: Revenue rose 11 percent to $4.42 billion, as sales of immune disorder treatment Enbrel and four other drugs climbed by double digits. But part of the revenue jump was due to price increases.
2013 FORECASTS: Amgen's forecast is for earnings per share of $6.85 to $7.15. It expects revenue of $17.8 billion to $18.2 billion — about the level it previously forecast for 2015.
Tags:
amgen, science_technology, income, generally accepted accounting principles, news summary, percent, fourth-quarter net income, income statement, double digits, price increases, marketing, revenue, share, profit drops, profit slump, consumer theory, disorder treatment enbrel, etanercept, sales surge, biotech giant amgen, revenue jump
